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Heart cells made from embryonic stem (ES) cells 
improve the function of injured mouse hearts, report 
Kolossov et al. (page  <ArtRef vol=”203” Iss=”10”>2315 </ArtRef>).
Cell replacement is an attractive therapy for heart 
failure, which is currently treatable only by organ 
transplant. But which source of cells makes the best 
starting material has been a matter of debate. Bone 
marrow cells were reported to provide some improvement 
in heart failure patients, but their benefit remains 
controversial. Kolossov et al. found no improvement of 
heart function when these cells were injected into mice 
with ischemic heart injury. Cardiomyocytes derived from 
ES cells, on the other hand, improved the contractility 
and blood pumping ability of the injured hearts.
The use of ES cells as starting material for this kind of 
therapy runs the risk of inducing tumors in the recipient due 
to small numbers of undifferentiated, pluripotent cells in 
the population. To limit this risk, Kolossov et al. used 
genetically engineered ES cells that allowed them to select 
for a virtually pure population of cardiomyocytes.
This selection trick, however, would have to be modified to be used in humans, as it introduces 
foreign DNA into the cells. In the meantime, the team plans to see whether similar success is 
achievable with ES-derived heart cells in larger animals, in which the contractile forces of heart beats 
are considerably stronger. 
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Leishmania parasites that lack an essential iron transporter lose the ability to replicate 
within macrophages. These parasites persist but do not lead to host pathology, report 
Chau Huynh et al. (page  <ArtRef vol=”203” Iss=”10”>2363 </ArtRef>). Targeting the newly identified LIT1 pathway could be a 
potential route to leishmaniasis therapy.
Intracellular parasites need iron to grow and multiply, but within the phagolysosome com-
partment, which such parasites inhabit, the supply of iron is limited. Specialized iron transporters 
had been identified in other intracellular pathogens, but none had been found in Leishmania, until 
now. Huynh and colleagues searched the Leishmania genome for sequences with similarity to 
known iron transporters and found a novel gene they call Leishmania iron transporter 1 (LIT1).
Having confirmed that LIT1 behaved as an iron transporter in yeast, the team deleted the gene 
from Leishmania to see how the bugs would fare in mouse macrophages. By 48 to 72 hours, the 
number of wild-type Leishmania per phagolysome compartment had significantly increased. LIT1−/− 
Leishmania, on the other hand, failed to multiply. Their phagolysosome homes appeared smaller, and 
the bugs themselves showed signs of degeneration. Whether these bugs would be eventually cleared 
from the cells is unknown, as macrophages do not survive well in culture beyond 72 hours.
Mice infected with wild-type Leishmania developed skin lesions indicative of cutaneous 
leishmaniasis. However, when infected with LIT1−/− Leishmania, no lesions appeared. Inter-
estingly, samples from the mice injected with LIT1−/− bugs still contained live Leishmania up 
to 6 months later, despite the pathology-free status of these mice. Removal of the iron 
transporter LIT1, thus, obliterates Leishmania’s virulence and renders the bug incapable of 
replication, yet does not kill it. The team is currently interested in determining the intracellular 
location of the surviving LIT1−/− bugs and in seeing whether this location allows them to 
acquire iron by an alternative route. This is an important question—if answered, it could lead to 
new treatments capable of completely eliminating the parasites from their infected hosts. 
ES-derived cardiomyocytes (green) fix a damaged mouse heart.
Replication of Leishmania inside 
phagolysome (top) fails when LIT1 
is deleted (bottom).